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A B S T R A C T
Anti-N-methyl-D-aspartate receptor encephalitis has become an increasingly recognized etiology of
acute psychosis in young patients. The diverse constellation of symptoms allows for misdiagnosis as an
infectious, psychological, or toxicological entity resulting in delays in treatment with increasing
morbidity. We describe a case of anti-NMDAR encephalitis that was a particular challenge to diagnose.
Practitioners should maintain a high index of suspicion for anti-NMDAR and related neuroautoimmune
syndromes, especially in young patients that present with acute mental status decline or dyskinesia.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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A 21-year-old female was admitted due to altered mental status
after 2 weeks of headache. One week earlier she was evaluated in
the emergency room and discharged on analgesics after a nonfocal
neurologic exam and unremarkable non-contrast head CT. Over
the following week her headaches increased in severity with the
development of nausea, subjective fevers, and photophobia. One
day prior to admission, she became emotionally labile and
incoherent.
On admission, the patient’s vitals were 38.6C, heart rate
111 bpm, 124/84 mm, respiratory rate 24 bpm, O2 saturation 98%
on ambient air. On exam, she had intermittent shaking of
extremities and episodes of staring into space intermixed with
inappropriate crying and laughing. She answered questions
incoherently and did not follow commands. Cardiopulmonary,
abdominal, and skin exam were unremarkable with rectal tone
intact. Her laboratory studies were signiﬁcant for white blood
count 15.8  103 cells/mL with an 87% neutrophil predominance.
Additionally, a toxicology panel, thyroid-stimulating hormone, and
urinalysis were negative. The patient underwent a lumbar
puncture with the following results; white blood count
298 cells/mL, 93% lymphocytes, red blood count 8 cells/mL, protein
122 mg/dL, lactate dehydrogenase 27 U/L, and glucose 47 mg/dL.* Corresponding author at: Department of Infectious Diseases, 3411 Wayne Avenue
Suite 4-H, Bronx, NY 10467, USA. Tel.: +1 718 920 5438; fax: +1 716 920 2746.
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3.0/).The patient had no travel history and no known toxin, tuberculosis,
rabies, or prion exposure.
On hospital day 3, the patient became unresponsive, hypoten-
sive, and hypoxic requiring intubation and initiation of pressors. A
repeat lumbar puncture was unchanged from admission. EEG
showed focal temporal slowing and frontal-intermittent-rhyth-
mic-delta activity consistent with diffuse cerebral dysfunction.
Repeat CT and MRI scans of the brain performed on day 3 and day
7 were unremarkable. Blood cultures, fungal blood cultures, and
cerebrospinal ﬂuid (CSF) cultures were negative. Throughout this
time the patient had been receiving empiric intravenous acyclovir
therapy which was discontinued on hospital day 8 after three
successive negative PCR tests for herpes simplex. Additional
studies including HIV test, syphilis serology, anti-nuclear antibody,
cryptocococcal antigen, and toxoplasma serology were negative.
CSF analysis for West Nile, Eastern Equine, Enterovirus, Ebstein-
Barr virus, Varicella, Cytolomegalovirus, Adenovirus, and St. Louis
encephalitis virus were negative. As an infectious etiology for the
patient’s symptoms was unable to be identiﬁed, an evaluation for
neoplastic etiologies was initiated. MRI of the chest, abdomen, and
pelvis was unremarkable except for a 2.2 cm simple physiologic
left ovarian cyst. Antibodies reactive to N-methyl-D-aspartate
receptors were detected both in CSF and in serum. Subsequently,
the patient was treated for NMDAR antibody mediated autoim-
mune encephalitis with high dose corticosteroids and plasma
exchange followed by intravenous immunoglobulin infusion.
Despite medical therapy, the patient continued to deteriorate
and her hospital course was complicated by persistent 39.5C
fevers, deep vein thrombosis, and while receiving anticoagulatione under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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determined to proceed with endocopic salpingo-oophorectomy.
Histologic exam of resected tissue identiﬁed a left mature cystic
teratoma. However, despite these interventions, the patient’s
mental status failed to recover and the patient eventually expired.
Discussion
Mental status change is a common trigger for infectious disease
consultation due to the myriad of potential pathogens that can cause
acute neurologic deterioration. Anti-N-methyl-D-aspartate receptor
(NMDAR) encephalitis was described in 2007 and has since become an
increasingly recognized etiology of progressive encephalitis. This
syndrome can have a diverse presentation including catatonia,
movement disorders, seizures, memory disturbance, and limbic
encephalitis. It is especially important to consider because the disease
process mimics aspects of schizophrenia and patients are initially
referred for psychiatric evaluation delaying appropriate diagnosis
[1]. The frequency of anti-NMDAR encephalitis may be grossly
underestimated. In a retrospective analysis, NMDAR antibodies were
identiﬁed in 1% of encephalitis cases of unknown origin [2]. In the
California Encephalitis Project, half of children with idiopathic
encephalitis and psychiatric symptoms had antibodies directed against
NMDAR. The frequency was four times that of encephalitis caused by
Herpes simplex, Varicella-zoster, and West Nile combined [3].
Anti-NMDAR encephalitis shows a female to male predominance
of 4:1 and classically occurs in younger patients. In the largest study
to date, of 577 cases 81% were female with median age of onset
21-years and 37% of patients younger than 18-years [4]. An
underlying neoplasm was present in 38% of patients and of those
with neoplastic disease 97% were female [4]. Ovarian teratomas
accounted for 94% of all neoplasms, with an additional 2% extra-
ovarian teratomas. Neuroblastoma, lymphoma, lung, breast, thymic,
testicular, and ovarian carcinoma have also been described [2,4]. In
all cases, removal of the tumor resulted in clinical improvement [3].
Patients with anti-NMDAR encephalitis have a progressive
syndrome with several recognized stages. An initial prodromal
phase occurs in 70% of patients consisting of headache, fever, nausea,
vomiting, diarrhea, or upper respiratory symptoms. Within 14-days
psychiatric symptoms develop including anxiety, insomnia, delu-
sions, paranoia, mania, or social withdrawal. Ataxia or choreiform
motions may be present. Short term memory loss is common, but
underestimated due to rapid language deﬁcits ranging from echolalia
to mutism and development of akinesis [2,3]. The ﬁnal stage presents
with dyskinesias, extrapyramidal signs, motor automatisms such as
lip-smacking, sustained jaw clenching, and autonomic instability
with hyperthermia, cardiac instability, hypersalivation, hypertension
or hypotension, incontinence, erectile dysfunction, and central
hypoventilation [2,3]. Complex seizures develop early in the disease
course. The frequency and intensity of seizures decrease with disease
progression; however, they may recur at any time [2].
Initially classiﬁed as paraneoplastic, increasing evidence sug-
gests that anti-NMDAR is a neuroautoimmune syndrome in which
antibodies form in response to a number of potential stimuli
[3]. Although predominantly associated with ovarian teratomas,
many other tumors are described and many patients have the
characteristic antibodies without evidence of neoplasm. In fact, anti-
NMDAR antibodies have been found in patients with a positive
mycoplasma serology, active herpes zoster infection, or following
vaccinations [2]. CSF and serum from afﬂicted patients have a
distinctive pattern of reactivity with hippocampus neurons
[5]. Antibodies appear to cross-react with synaptic proteins causing
reversible reduction in glutamate receptors [6]. However, the
initiating event causing antibody production has not been clariﬁed.
Diagnosis of anti-NMDAR encephalitis is dependent upon
identiﬁcation of circulating CSF or serum antibodies. In 250 pairedCSF and serum samples, antibodies were present in 100% of CSF
and only 85% of serum samples [6]. This is not surprising, as
intrathecal antibody production has been identiﬁed and CSF titers
appear to correlate with disease activity; neurologic improvement
had an associated decrease in titers [5]. The CSF typically has a
lymphocytic pleocytosis and elevated protein and oligoclonal
bands may be present [6]. Brain biopsy is not diagnostic; biopsies
of 15 patients had normal or nonspeciﬁc histology [2]. Approxi-
mately half of patients have irregularities on MRI. EEG is abnormal
but nonspeciﬁc in over 90% of persons.
The cornerstone of treatment is immunotherapy and tumor
removal. High dose corticosteroids, intravenous immunoglobulin,
and plasma exchange are considered primary therapy. In addition,
identiﬁcation and resection of underlying tumor aids recovery.
Approximately half of patients show clinical improvement within
4-weeks with primary therapy. Second line therapy includes
monoclonal antibodies (Rituximab) and cyclophosphamide.
With prompt and aggressive treatment, the overall prognosis
remains favorable with 75% of patients having a complete recovery
or mild residual sequellae. However, the remaining 25% of patients
had residual symptomatology that severely affected quality of life.
Titulaer, et al. postulated a 7% mortality rate while Dalmu et al.,
observed a 4% mortality in their 360 case cohort with cause of death
due to autonomic instability and complications of prolonged
hospitalization [2–4]. Independent predictors of favorable outcome
include lower initial severity of symptoms, not requiring admission
to intensive care, and prompt initiation of treatment [4]. This
presents the challenge of whether to perform resection, typically
salpingo-oophrectomy, in young patients. In fact, in 197 cases, the
median time from symptom onset to surgical resection was
1.4 months [6]. In all cases, there is a protracted recovery phase
which can last up to three years [3,4]. Relapse of encephalitis occurs
in 20–25% of patients from 3-months to 9 years [2,3].
Anti-NMDAR encephalitis is a syndrome which is increasingly
recognized as a cause of acute psychosis in young people. It has
been misdiagnosed as viral encephalitis, rabies, schizophrenia or
psychosis, neuroleptic malignant syndrome, dissociative neuro-
leptic use, or seizure disorder. Early diagnosis is critical and
improves outcomes, but remains a particular challenge, as our
patient had an ovarian teratoma that resembled a simple cyst on
imaging. Ultimately, anti-NMDAR disease should be suspected in
any individual younger than 50, especially a child or teenager, that
develops rapid psychosis or movement disorder. Identiﬁcation of
NMDAR antibodies conﬁrms the diagnosis and should prompt
early intervention with immunotherapy and neoplastic workup.
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